The GHITM Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the GHITM gene in the human Raji B-lymphocyte line. This polyclonal knockout pool provides a heterogeneous loss-of-function model for investigating GHITM-dependent mitochondrial regulation and apoptosis control, without clonal bias. The cells are delivered as a research-ready population, suitable for functional genomics, signaling pathway analysis, and drug discovery applications in B-cell malignancy contexts.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive B-cell line derived from a Burkitt’s lymphoma patient. Raji cells express characteristic B-cell surface markers including CD19 and CD20, and are widely used as a model for B-cell biology, EBV-associated lymphomagenesis, and hematopoietic malignancies. Their robust proliferative capacity and well-characterized signaling networks make them an ideal chassis for studying mitochondrial apoptosis pathways and oncogenic survival mechanisms.
GHITM (Growth Hormone Inducible Transmembrane Protein) is a mitochondrial inner membrane protein that critically preserves cristae architecture and restricts cytochrome c mobilization during apoptotic stimuli. It functions downstream of growth hormone and acts through JAK2/STAT5 signaling; its expression is also regulated by the tumor suppressor p53. GHITM interacts with anti-apoptotic proteins BCL2 and BCL-XL, and physically associates with Prohibitin-2, to inhibit BAX/BAK oligomerization and mitochondrial outer membrane permeabilization. This interaction prevents cytochrome c release, thereby blocking caspase-9 and caspase-3 activation and maintaining mitochondrial integrity. Conversely, loss of GHITM disinhibits intrinsic apoptosis, promoting mitochondrial fragmentation and sensitizing cells to death signals.
In the Raji B-cell lymphoma background, GHITM knockout provides a pertinent model to examine how mitochondrial apoptosis resistance contributes to B-cell malignancies and therapy resistance. EBV-driven lymphomagenesis often involves modulation of apoptotic pathways, and GHITM??s anti-apoptotic role may intersect with viral oncogene signaling. This polyclonal knockout system enables dissection of mitochondrial dynamics, cristae remodeling, and calcium homeostasis in a lymphoma setting, offering insights into BCL2 family dependency, cytochrome c regulation, and the interplay between growth hormone signaling and B-cell survival. The model is valuable for probing the molecular basis of drug resistance in leukemia and lymphoma.
Researchers can utilize GHITM Knockout Raji Polyclonal Cells in varied experimental paradigms. Western blotting and RT-qPCR quantify downstream effectors such as BAX, BCL2, cytochrome c, and cleaved caspases. Apoptosis induction is assessed via Annexin V flow cytometry, while JC-1 staining measures mitochondrial membrane potential. Cytochrome c release assays and immunofluorescence for mitochondrial fragmentation provide direct functional readouts. Co-immunoprecipitation studies can probe interactions with BCL2 family members and Prohibitin-2. Combinatorial drug sensitivity assays can screen for agents that exploit GHITM loss, particularly BH3 mimetics. For additional information, please contact Ascent Research.
